Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose aspirin for prevention of hypertensive disorders of pregnancy in South Africa
ISRCTN43031232Phase 3Completed
- Sponsor
- University of KwaZulu-Natal
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in maternal hypertension (HDP), preeclampsia and pregnancy-induced hypertension (PIH) (2 arms), sponsored by University of KwaZulu-Natal. Primary endpoint: Incidence of hypertensive disorders of pregnancy. Started May 2021; status: completed.
02
Drugs
aspirin
03
Conditions
maternal hypertension (HDP)preeclampsiapregnancy-induced hypertension (PIH)
Beyond the preview
Go deeper on ISRCTN43031232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43031232.